Repositioning drugs by targeting network modules: a Parkinson’s disease case study

Abstract

BackgroundMuch effort has been devoted to the discovery of specific mechanisms between drugs and single targets to date. However, as biological systems maintain homeostasis at the level of functional networks robustly controlling the internal environment, such networks commonly contain multiple redundant mechanisms designed to counteract loss or perturbation of a single member of the network. As such, investigation of therapeutics that target dysregulated pathways or processes, rather than single targets, may identify agents that function at a level of the biological organization more relevant to the pathology of complex diseases such as Parkinson’s Disease (PD). Genome-wide association studies (GWAS) in PD have identified common variants underlying disease susceptibility, while gene expression microarray data provide genome-wide transcriptional profiles. These genomic studies can illustrate upstream perturbations causing the dysfunction in signaling pathways and downstream biochemical mechanisms leading to the PD phenotype. We hypothesize that drugs acting at the level of a gene expression module specific to PD can overcome the lack of efficacy associated with targeting a single gene in polygenic diseases. Thus, this approach represents a promising new direction for module-based drug discovery in human diseases such as PD.ResultsWe built a framework that integrates GWAS data with gene co-expression modules from tissues representing three brain regions—the frontal gyrus, the lateral substantia, and the medial substantia in PD patients. Using weighted gene correlation network analysis (WGCNA) software package in R, we conducted enrichment analysis of data from a GWAS of PD. This led to the identification of two over-represented PD-specific gene co-expression network modules: the Brown Module (Br) containing 449 genes and the Turquoise module (T) containing 905 genes. Further enrichment analysis identified four functional pathways within the Br module (cellular respiration, intracellular transport, energy coupled proton transport against the electrochemical gradient, and microtubule-based movement), and one functional pathway within the T module (M-phase). Next, we utilized drug-protein regulatory relationship databases (DMAP) and developed a Drug Effect Sum Score (DESS) to evaluate all candidate drugs that might restore gene expression to normal level across the Br and T modules. Among the drugs with the 12 highest DESS scores, 5 had been reported as potential treatments for PD and 6 hold potential repositioning applications.ConclusionIn this study, we present a systems pharmacology framework which draws on genetic data from GWAS and gene expression microarray data to reposition drugs for PD. Our innovative approach integrates gene co-expression modules with biomolecular interaction network analysis to identify network modules critical to the PD pathway and disease mechanism. We quantify the positive effects of drugs in a DESS score that is based on known drug-target activity profiles. Our results illustrate that ...

Stress resilience is promoted by a Zfp189-driven transcriptional network in prefrontal cortex

“…By clustering genes into units (modules) based on coordinated transcriptional regulation, network-based analytical methods such as weighted gene co-expression network analysis (WGCNA) provide an alternative approach to standard differential expression analysis of large transcriptional datasets. WGCNA has been used to define gene networks from RNA-sequencing (RNA-seq) of human post-mortem brain in complex disorders such as schizophrenia 4 , Parkinson’s disease 5 , Alzheimer’s disease 6 , autism 7 and MDD 8 , 9 . However, because these studies involve in silico analysis of human brain RNA-seq data, the causality of the inferred relationships cannot be determined through in vivo experiments.…”

A Consensus Proteomic Analysis of Alzheimer’s Disease Brain and Cerebrospinal Fluid Reveals Early Changes in Energy Metabolism Associated with Microglia and Astrocyte Activation

“…Communities of co-expressed proteins can be linked to disease processes, and the most strongly correlated proteins, or "hubs," within these coexpression modules are enriched in key drivers of disease pathogenesis [13][14][15][16][17][18] . Therefore, targeting hubs within protein co-expression modules most related to disease biology is a promising approach for drug and biomarker development [19][20][21][22] . We recently analyzed control, asymptomatic AD, and AD brain tissue, using both protein differential and co-expression approaches, in a cohort of 47 individuals from the Baltimore Longitudinal Study of Aging to better understand the proteomic changes that occur in AD brain 23,24 .…”

Exploring Drug Treatment Patterns Based on the Action of Drug and Multilayer Network Model

“…Although each gene in the drug-target module may not be helpful for disease treatment, combinations of the genes within the module may play important roles in disease treatment [ 16 ]. By targeting multiple genes in the drug-target module, it may be possible to identify the function of genes related to complex disease pathology at the tissue level [ 17 , 18 ].…”